Isbn: 9781498709552 - bayesian designs for phase i-ii clinical trials (chapman & hall/crc biostatistics, band 92) (17 Ergebnisse)

Zustand: New.

Zustand: New.

Zustand: New.

Zustand: New.

Hardback. Zustand: New. New copy - Usually dispatched within 4 working days.

Zustand: New.

Zustand: New. In English.

Zustand: As New. Unread book in perfect condition.

Hardcover. Zustand: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Zustand: As New. Unread book in perfect condition.

Hardcover. Zustand: Brand New. 1st edition. 310 pages. 9.25x6.25x0.75 inches. In Stock.

Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Ying Yuan is a professor and co-chief of the Section of Adaptive Clinical Trials in the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. He is also an adjunct associate professor in the Department of Stat.…

Buch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I-II Clinical Trials describes how phase I-II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes.Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity. 326 pp. Englisch.…

Hardback. Zustand: New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days.

HRD. Zustand: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Zustand: New. PRINT ON DEMAND.

Buch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Reliably optimizing a new treatment in humans is a critical first step in clinical evaluation since choosing a suboptimal dose or schedule may lead to failure in later trials. At the same time, if promising preclinical results do not translate into a real treatment advance, it is important to determine this quickly and terminate the clinical evaluation process to avoid wasting resources. Bayesian Designs for Phase I-II Clinical Trials describes how phase I-II designs can serve as a bridge or protective barrier between preclinical studies and large confirmatory clinical trials. It illustrates many of the severe drawbacks with conventional methods used for early-phase clinical trials and presents numerous Bayesian designs for human clinical trials of new experimental treatment regimes.Written by research leaders from the University of Texas MD Anderson Cancer Center, this book shows how Bayesian designs for early-phase clinical trials can explore, refine, and optimize new experimental treatments. It emphasizes the importance of basing decisions on both efficacy and toxicity.…